Divi's Laboratories Overview

Divi's Laboratories is a leading player in the pharmaceutical industry, with a rich history dating back to 1990. The company was founded by S. Radhakrishna and S. N. Venkatesh.

Divi's Laboratories is headquartered in Hyderabad, India, and has established itself as a major player in the global pharmaceutical market. It has a strong presence in the US, Europe, and other emerging markets.

The company's journey began with the development of a manufacturing facility in Hyderabad, which was later expanded to meet growing demand. Today, Divi's Laboratories operates from a state-of-the-art facility that adheres to international standards of quality and safety.

Discover more: West Pharmaceutical Services

Divi's Laboratories has a strong presence in manufacturing, with units located in various parts of India. Their manufacturing facilities are spread across different regions, including Telangana and Andhra Pradesh.

The company has a manufacturing unit in Choutuppal, Yadadri Bhuvanagiri district, Telangana, which is also home to the DC SEZ Unit. Another important facility is the Export Oriented Unit in Chippada village, Bheemunipatnam mandal, Visakhapatnam district, Andhra Pradesh.

You might like: United States Bankruptcy Court, District of Arizona

The company has several other manufacturing units in the same region, including the Divi's Pharma SEZ Unit, DSN SEZ Unit, and DCV SEZ Unit, all located in Chippada village, Bheemunipatnam mandal, Visakhapatnam district, Andhra Pradesh.

Here are some of the key manufacturing units of Divi's Laboratories:

In addition to manufacturing, Divi's Laboratories also has a dedicated facility for producing nutraceuticals, which includes active ingredients and finished forms of carotenoids.

Divi's Laboratories has shown a consistent sales growth, albeit at a slow pace, with sales figures ranging from 1,708 to 2,585 crores over the last few quarters. The company's sales have been steadily increasing, but at a rate that may not be as impressive as some investors might have hoped.

The operating profit margin (OPM) of the company has been volatile, fluctuating between 24% and 38% over the last year. This volatility is likely due to the company's significant working capital, which is dragging its return on equity (ROE) and return on capital employed (ROCE).

Here are the quarterly sales and operating profit figures for Divi's Laboratories:

The profit and loss statement is a crucial part of any company's financial performance. It shows the revenue earned and the expenses incurred during a particular period.

The company's sales have been steadily increasing, with a high of Rs. 2,585 crores in Jun 2025 and a low of Rs. 1,708 crores in Dec 2022. The sales have been growing at a rate of 12.34% per quarter on average.

Expenses have also been on the rise, with a high of Rs. 1,699 crores in Jun 2025 and a low of Rs. 1,234 crores in Sep 2022. The company's operating profit has been impacted by the increasing expenses, but it has still managed to maintain a healthy operating profit margin of 34% in Jun 2025.

The company's net profit has also been increasing, with a high of Rs. 662 crores in Jun 2025 and a low of Rs. 306 crores in Dec 2022. The net profit margin has been steadily improving, from 13.11% in Jun 2023 to 24.94% in Jun 2025.

Here's a summary of the company's profit and loss performance over the past year:

The company's EPS has also been improving, with a high of Rs. 24.94 in Jun 2025 and a low of Rs. 11.53 in Dec 2022.

The company's share price has increased over the last 10 years due to earnings. This is a positive sign, but we need to consider the bigger picture.

ROE has increased over the last 10 years, and asset turnover is responsible for this increase. This suggests that the company is becoming more efficient in its operations.

Debt is an important consideration, and the company should not have issues servicing its debt. A strong balance sheet is also a good sign, but it might have issues paying its suppliers.

The company's RoCE has been consistently strong, which is a testament to its financial health. However, it's worth noting that RoCE has decreased even without significant capex, which could be a cause for concern.

The company is trading at a premium to its 3-year historic valuations, which might be a warning sign for investors. We need to consider whether the price is justified by the company's performance.

Here's a summary of the key points:

Divi's Laboratories has a strong presence in the international pharmaceutical industry, thanks to its major subsidiaries that enhance its operational capabilities and market reach.

The company's subsidiaries play a fundamental role in its global outreach and operations, enabling it to cement its place in the industry.

Divi's Laboratories has successfully expanded its operations through its subsidiaries, which have contributed to its growth and success.

The company's subsidiaries have allowed it to reach a wider market and establish itself as a major player in the pharmaceutical industry.

Readers also liked: Reach Plc

Divi's Laboratories is one of the leading pharmaceutical companies in India, but how does it stack up against its competitors? Let's take a look at the numbers.

The company has a significant presence in the country, with its headquarters located in Hyderabad, Telangana, just like Granules India Ltd. Divi's Laboratories also has a large workforce, employing over 17,500 people.

Here's a comparison of the number of employees among its competitors:

All of these companies are publicly traded, which gives investors a level of transparency and accountability.